Ornithine transcarbamylase deficiency

For patient information, click here

Ornithine transcarbamylase deficiency
Ornithine
ICD-9	270.6
OMIM	311250
DiseasesDB	9286
MedlinePlus	000372
eMedicine	ped/2744
MeSH	D020163

WikiDoc Resources for Ornithine transcarbamylase deficiency
Articles
Most recent articles on Ornithine transcarbamylase deficiency Most cited articles on Ornithine transcarbamylase deficiency Review articles on Ornithine transcarbamylase deficiency Articles on Ornithine transcarbamylase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ornithine transcarbamylase deficiency Images of Ornithine transcarbamylase deficiency Photos of Ornithine transcarbamylase deficiency Podcasts & MP3s on Ornithine transcarbamylase deficiency Videos on Ornithine transcarbamylase deficiency
Evidence Based Medicine
Cochrane Collaboration on Ornithine transcarbamylase deficiency Bandolier on Ornithine transcarbamylase deficiency TRIP on Ornithine transcarbamylase deficiency
Clinical Trials
Ongoing Trials on Ornithine transcarbamylase deficiency at Clinical Trials.gov Trial results on Ornithine transcarbamylase deficiency Clinical Trials on Ornithine transcarbamylase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ornithine transcarbamylase deficiency NICE Guidance on Ornithine transcarbamylase deficiency NHS PRODIGY Guidance FDA on Ornithine transcarbamylase deficiency CDC on Ornithine transcarbamylase deficiency
Books
Books on Ornithine transcarbamylase deficiency
News
Ornithine transcarbamylase deficiency in the news Be alerted to news on Ornithine transcarbamylase deficiency News trends on Ornithine transcarbamylase deficiency
Commentary
Blogs on Ornithine transcarbamylase deficiency
Definitions
Definitions of Ornithine transcarbamylase deficiency
Patient Resources / Community
Patient resources on Ornithine transcarbamylase deficiency Discussion groups on Ornithine transcarbamylase deficiency Patient Handouts on Ornithine transcarbamylase deficiency Directions to Hospitals Treating Ornithine transcarbamylase deficiency Risk calculators and risk factors for Ornithine transcarbamylase deficiency
Healthcare Provider Resources
Symptoms of Ornithine transcarbamylase deficiency Causes & Risk Factors for Ornithine transcarbamylase deficiency Diagnostic studies for Ornithine transcarbamylase deficiency Treatment of Ornithine transcarbamylase deficiency
Continuing Medical Education (CME)
CME Programs on Ornithine transcarbamylase deficiency
International
Ornithine transcarbamylase deficiency en Espanol Ornithine transcarbamylase deficiency en Francais
Business
Ornithine transcarbamylase deficiency in the Marketplace Patents on Ornithine transcarbamylase deficiency
Experimental / Informatics
List of terms related to Ornithine transcarbamylase deficiency

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ornithine transcarbamylase deficiency (OTCD), the most common of the urea cycle disorders, is a rare metabolic disorder, occurring in one out of every 80,000 births. OTC is a genetic disorder resulting in a mutated and ineffective form of the enzyme ornithine transcarbamylase.

Symptoms

Like other urea cycle disorders, OTC affects the body's ability to get rid of ammonia, a toxic breakdown product of the body's use of protein. As a result, ammonia accumulates in the blood causing hyperammonemia. This ammonia travels to the various organs of the body including the brain, causing coma, brain damage and death.

Another symptom of OTC is a buildup of orotic acid in the blood. This is due to an anaplerism that occurs with carbamoyl phosphate entering the pyrimidine synthesis pathway.

Ornithine transcarbamylase deficiency often becomes evident in the first few days of life. An infant with ornithine transcarbamylase deficiency may be lacking in energy (lethargic) or unwilling to eat, and have poorly-controlled breathing rate or body temperature. Some babies with this disorder may experience seizures or unusual body movements, or go into a coma. Complications from ornithine transcarbamylase deficiency may include developmental delay and mental retardation. Progressive liver damage, skin lesions, and brittle hair may also be seen. Other symptoms include irrational behavior (caused by encephalitis), mood swings, and poor performance in school.

In some affected individuals, signs and symptoms of ornithine transcarbamylase may be less severe, and may not appear until later in life. Some female carriers become symptomatic later in life. This can happen as a result of anorexia, starvation, malnutrition, or even (in at least one case) as a result of gastric bypass surgery. It is also possible for symptoms to be exacerbated by extreme trauma of many sorts, including, (at least in one case) adolescent pregnancy coupled with severe stomach flu.

Genetics

Mutations in the OTC gene cause ornithine transcarbamylase deficiency. Ornithine transcarbamylase deficiency belongs to a class of genetic diseases called urea cycle disorders. The urea cycle is a sequence of reactions that occurs in liver cells. It processes excess nitrogen, generated when protein is used by the body, to make a compound called urea that is excreted by the kidneys.

In ornithine transcarbamylase deficiency, the enzyme that starts a specific reaction within the urea cycle is damaged or missing. The urea cycle cannot proceed normally, and nitrogen accumulates in the bloodstream in the form of ammonia. Ammonia is especially damaging to the nervous system, so ornithine transcarbamylase deficiency causes neurological problems as well as eventual damage to the liver.

Ornithine transcarbamylase deficiency is an X-linked disorder caused by a number of different mutations. Since the gene is on the X chromosome, females are primarily carriers while males with nonconservative mutations rarely survive past 72 hours of birth. Half of those survivors die in the first month, and half of the remaining by age 5.

Treatment

Treatment includes a low-protein formula called keto-acid and sodium benzoate, a preservative, and another type of sodium, which binds to ammonia and helps eliminate it from the body. Some treatment includes a protein limited diet combined with a dietary supplement including arginine.

In cases of OTC where enzyme production is low or non-existent, treatment consisting of low-protein diet and dietary supplementation are inadequate. In these cases, liver transplant is a treatment option.

Reference

• National Library of Medicine Ornithine transcarbamylase deficiency

Template:WikiDoc Sources